Biohaven logo

Biohaven Share Price Today

(NASDAQ: BHVN)

Biohaven share price is $20.37 & ₹1,740.92 as on 18 Apr 2025, 2.30 'hrs' IST

$20.37

1.69

(9.05%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Biohaven share price in Dollar and Rupees. Guide to invest in Biohaven stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Biohaven, along with analyst recommendations, forecasts, and comprehensive financials.

Biohaven share price movements

  • Today's Low: $18.81
    Today's High: $20.47

    Day's Volatility :8.11%

  • 52 Weeks Low: $15.79
    52 Weeks High: $55.70

    52 Weeks Volatility :71.65%

Biohaven (BHVN) Returns

PeriodBiohaven LtdIndex (Russel 2000)
3 Months
-47.81%
0.0%
6 Months
-60.32%
0.0%
1 Year
-47.76%
0.0%
3 Years
-80.16%
-12.9%

Biohaven (BHVN) Key Statistics

in dollars & INR

Previous Close
$18.68
Open
$18.99
Today's High
$20.47
Today's Low
$18.81
Market Capitalization
$2.1B
Today's Volume
$2.1M
52 Week High
$55.7
52 Week Low
$15.79
Revenue TTM
$0.0
EBITDA
$-866.4M
Earnings Per Share (EPS)
$-9.28
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-198.83%

How to invest in Biohaven Stock (BHVN) from India?

It is very easy for Indian residents to invest directly in Biohaven from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biohaven stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biohaven or BHVN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biohaven or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biohaven shares which would translate to 0.042 fractional shares of Biohaven as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biohaven, in just a few clicks!

Returns in Biohaven (BHVN) for Indian investors in Rupees

The Biohaven stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Biohaven investment value today

Current value as on today

₹54,585

Returns

₹45,415

(-45.41%)

Returns from Biohaven Stock

₹47,756 (-47.76%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Biohaven (BHVN)

100.0%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Investment in Biohaven Shares from India has grown by 100.0% over the past 30 days, indicating increased transactional activity.

87%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Biohaven Stock from India on INDmoney has increased by 87% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Biohaven

  • Vanguard Group Inc

    8.24%

  • BlackRock Inc

    7.51%

  • HHG PLC

    6.84%

  • Stifel Financial Corp

    6.43%

  • Suvretta Capital Management, LLC

    5.51%

  • Farallon Capital Management, L.L.C.

    4.34%

Analyst Recommendation on Biohaven

Rating
Trend

Buy

    94%Buy

    5%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Biohaven(by analysts ranked 0 to 5 stars)

Analyst Forecast on Biohaven Stock (BHVN)

What analysts predicted

Upside of 199.46%

Target:

$61.00

Current:

$20.37

Insights on Biohaven Stock (Ticker Symbol: BHVN)

  • Price Movement

    In the last 7 days, BHVN stock has moved up by 15.6%
  • BHVN vs ONC (1 yr)

    In the last 1 year, Beone Medicines Ltd has given 78.3% return, outperforming this stock by 126.1%
  • BHVN vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 30.5% return, outperforming this stock by 111.0%

Biohaven Technicals Summary

Sell

Neutral

Buy

Biohaven is currently in a neutral trading position according to technical analysis indicators.

Biohaven (BHVN) Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Biohaven Ltd logo
-27.71%
-60.32%
-47.76%
-80.16%
-51.27%
Regeneron Pharmaceuticals, Inc. logo
-15.01%
-41.85%
-37.2%
-21.74%
-0.85%
Beone Medicines Ltd logo
-12.04%
5.03%
78.34%
40.23%
43.44%
Vertex Pharmaceuticals Incorporated logo
-4.13%
2.3%
24.05%
71.43%
78.99%
Alnylam Pharmaceuticals, Inc. logo
-7.49%
-19.67%
62.43%
39.66%
61.91%

Biohaven Dividend announcements

  • Biohaven Earnings

    Biohaven’s price-to-earnings ratio stands at None

About Biohaven

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Organization
Biohaven
Employees
256
CEO
Dr. Vladimir Coric M.D.
Industry
Health Technology

Management People of Biohaven

NameTitle
Dr. Vladimir Coric M.D.
Chairman & CEO
Mr. Matthew Buten
Chief Financial Officer
Dr. Bruce D. Car DACVP, Ph.D.
Chief Scientific Officer
Ms. Kimberly Gentile
Senior Vice President of Clinical Operations
Ms. Deb Young
Senior Director of Regulatory Affairs & Operations
Mr. George C. Clark CPA
VP & Chief Accounting Officer
Ms. Jennifer Porcelli
Vice President of Investor Relations
Mr. Warren Volles J.D.
General Counsel & Chief Legal Officer
Mr. Clifford Bechtold M.S.
President, GM of Biohaven Ireland & Chief Compliance Officer
Mr. John Tilton
Chief Commercial Officer of Rare Diseases

Important FAQs about investing in BHVN Stock from India :

What is Biohaven share price today?

Biohaven share price today stands at $20.37, Open: $18.99 ; Previous Close: $18.68 ; High: $20.47 ; Low: $18.81 ; 52 Week High: $55.70 ; 52 Week Low: $15.79.

The stock opens at $18.99, after a previous close of $18.68. The stock reached a daily high of $20.47 and a low of $18.81, with a 52-week high of $55.70 and a 52-week low of $15.79.

Can Indians buy Biohaven shares?

Yes, Indians can invest in the Biohaven (BHVN) from India.

With INDmoney, you can buy Biohaven at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Biohaven at zero transaction cost.

How can I buy Biohaven shares from India?

It is very easy to buy Biohaven from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biohaven (BHVN) be purchased?

Yes, you can buy fractional shares of Biohaven with INDmoney app.

What are the documents required to start investing in Biohaven stocks?

To start investing in Biohaven, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Biohaven Stock (BHVN)?

Today’s highest price of Biohaven (BHVN) is $20.47.

Today’s lowest price of Biohaven (BHVN) is $18.81.

What is today's market capitalisation of Biohaven?

Today's market capitalisation of Biohaven BHVN is 2.1B

What is the 52 Week High and Low Range of Biohaven Stock (BHVN)?

  • 52 Week High

    $55.70

  • 52 Week Low

    $15.79

What are the historical returns of Biohaven (BHVN)?

  • 1 Month Returns

    -27.71%

  • 3 Months Returns

    -60.32%

  • 1 Year Returns

    -47.76%

  • 5 Years Returns

    -51.27%

Who is the Chief Executive Officer (CEO) of Biohaven ?

Dr. Vladimir Coric M.D. is the current Chief Executive Officer (CEO) of Biohaven.